

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中國 9 號 健康 產業 有限 公司
China Jiu hao Health Industry Corporation Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 419)

PROFIT WARNING

This announcement is made by China Jiu hao Health Industry Corporation Limited (the “Company”) and its subsidiaries (collectively the “Group”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“Listing Rules”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Future Ordinance (Chapter 571, the Laws of Hong Kong).

The board of directors of the Company (the “Board”) wishes to inform shareholders of the Company and potential investors that, based on the Group’s preliminary unaudited assessment for the year ended 31 December 2015 (the “Year”), the Group is expected to record an annual consolidated net loss attributable to equity shareholders of the Company for the Year of approximately HK\$500 million, whereas the Group recorded a net profit attributable to equity shareholders of the Company for the year ended 31 December 2014 of HK\$55 million.

The expected net loss is primarily due to:

- the incurrence of loss on disposal of subsidiaries, after taxes, of approximately HK\$300 million, which is mainly attributed to the completion of a very substantial disposal transaction (“VSD”) in October 2015 (details of which were disclosed in the Company’s circular dated 23 June 2015 and the Company’s announcement dated 6 October 2015)
- the incurrence of legal and professional fees of approximately HK\$54 million for the VSD
- provision for impairment of certain non-current assets and current assets of the Group of approximately HK\$190 million, which is mainly attributed to the provision for impairment of the interests in joint ventures and the amounts due from joint ventures and its subsidiaries

- the incurrence of exchange loss arising from depreciation of Renminbi against Hong Kong dollars during the Year of approximately HK\$34 million

As the annual results have not yet been finalized, the information contained in this announcement is based on information that is currently available and the preliminary unaudited consolidated management accounts of the Group for the Year which have not yet been reviewed by the Company's audit committee and have not been audited by the Company's independent auditor. The annual results are expected to be published on or before 31 March 2016.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

For and on behalf of the Board
CHINA JIUHAO HEALTH INDUSTRY CORPORATION LIMITED
Raymond Hau
Company Secretary

Hong Kong, 11 February 2016

As at the date of this announcement, the Board comprises:

Executive directors: Mr. WANG Zhongjun (Chairman), Mr. LAU Seng Yee (Vice Chairman); Mr. WANG Zhonglei, Mr. LIN Haifeng, Ms. WANG Dongmei, Mr. YUEN Hoi Po
Independent non-executive directors: Dr. WONG Yau Kar David, BBS, JP, Mr. YUEN Kin, Mr. CHU Yuguo